



USAID
FROM THE AMERICAN PEOPLE

FHMENGAGE
Healthy Markets for Healthy People

Frontier Health Markets (FHM) Engage

YEAR I PERFORMANCE INDICATOR REPORT
Supplement to the Year I Annual Report for the
period of September 27, 2021, to September 30, 2022

December 12, 2022

Frontier Health Markets (FHM) Engage

YEAR I PERFORMANCE INDICATOR REPORT

Supplement to the Year I Annual Report for the
period of September 27, 2021, to September 30, 2022

Authors:

Lauren Rosapep, Arthur Ostrega, and Taylor Salisbury

Acknowledgements:

The cooperation and invaluable input from all the stakeholders engaged in the development of this report is acknowledged and appreciated.

Cooperative Agreement No:

7200AA21CA00027 (2021-2026)

Submitted to:

USAID

Prepared by:

© Chemonics 2022. All rights reserved.

1275 New Jersey Ave. SE, Ste 200,
Washington, DC 20003

DISCLAIMER

This material is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of cooperative agreement no. 7200AA21CA00027 (2021-2026). The contents are the responsibility of Chemonics International and do not necessarily reflect the views of USAID or the United States Government.

Contents

Acronyms.....iii

Background and Context 1

 Mapping indicators to activities..... 1

Achievements in Year I 11

Tables

Table 1: Mapping of Performance Indicators to Activities..... 4

Table 2: Summary of Results..... 12

Figures

Figure 1: FHM Engage Logic Model..... 2

Figure 2: FHM Engage Results Framework Error! Bookmark not defined.

Acronyms

AMELP	Activity Monitoring, Evaluation, and Learning Plan
FP	Family Planning
IR	Intermediate Result
M&E	Monitoring and Evaluation
MEAL	Monitoring, Evaluation, and Adaptive Learning
PIRS	Performance Indicator Reference Sheet

Background and Context

The FHM Engage global Activity Monitoring, Evaluation, and Learning Plan (AMELP) was approved at the end of August 2022 as the FHM Engage team was finalizing implementation of Year 1 activities. The AMELP includes a program logic model (Figure 1 below) that describes FHM Engage’s approach to generating results and a corresponding results framework (Figure 2 below) that describes the outcomes FHM Engage seeks to achieve as it produces these results. The results framework is complemented by a set of 51 performance indicators that FHM Engage will track and report on at the global level over the coming years. Following the approval of the AMELP, the Monitoring, Evaluation, and Adaptive Learning (MEAL) team began operationalizing the performance indicators, with the goal of having a fully operational performance monitoring system in place for reporting in the first reporting cycle of FY2023 in April 2023.

Typically, FHM Engage would include a summary report of the results for the performance indicators as an annex to the annual report. In the Year 1 reporting period in October 2022, FHM Engage was unable to report on the performance indicators in this manner since the AMELP had been finalized shortly before this timeframe, and the MEAL team was still in the process of setting up the performance monitoring system. This set up includes developing complete indicator definitions, developing Performance Indicator Reference Sheets (PIRS) for each indicator, mapping indicators to activities, setting up data collection protocols, etc. FHM Engage agreed with the AOR team that it would report separately on the performance indicator results for Year 1 in mid-December 2022. Beginning in Year 2 and onward, as outlined in the AMELP, FHM Engage will report performance indicators on a bi-annual basis as part of the semi-annual and annual reports.

Additionally, FHM Engage and the AOR teams agreed that this December 2022 report would focus on providing relevant data points on the sub-set of indicators most relevant to Year 1 implementation, which are the indicators connected to Intermediate Results (IRs) 1.1 (Stewardship) and 1.4 (Market Intelligence). This report provides the data on these sub-set of indicators. Due to additional progress made in defining the performance indicators, this report also includes data on performance indicators connected to IRs 1.2 (Financing) and 1.3 (Rules and Norms). As agreed, this report reflects data drawn from the Core work plan activities, as well as data from the Liberia and Tanzania buy-in activities. The Nigeria and Madagascar buy-ins were not in active implementation during Year 1, so this report does not include data from those buy-ins. These buy-ins will be included in future reporting periods. Finally, as agreed, baselines and targets for the indicators will be included, as relevant, in the next reporting period report in April 2023.

Mapping indicators to activities

To support reporting on the performance indicators, FHM Engage mapped each of the 51 performance indicators to each of the Core work plan activities and to the Liberia and Tanzania buy-in activities as a whole. This mapping is shown in Table 1 below. Each **bolded X** in the table represents an instance where the activity will likely produce relevant data for the corresponding indicator at some point over FHM Engage’s period of performance. Indicators with relevant data from Year 1 are shaded in light yellow. There is sizable variation in the mapping across activities, with some activities connecting to many indicators and others connecting to just one or two. Similarly, looking across indicators, some indicators connect to almost all activities, while others connect to very few.

FIGURE I: FHM ENGAGE LOGIC MODEL

Note: This is the approved logic model for FHM Engage in the AMELP. Given recent discussions on FP market descriptions, we can revisit in future, as needed.




FIGURE 2: FHM ENGAGE RESULTS FRAMEWORK




TABLE 2: MAPPING OF PERFORMANCE INDICATORS TO ACTIVITIES

Note: Each **bolded X** in the table represents an instance where the activity will likely produce relevant data for the corresponding indicator at some point over FHM Engage’s period of performance. **Light yellow shading** in the column Global Indicator Name denotes indicators for which there is data from Year 1 activities. For each activity column, indicators that are relevant to that activity and for which there is data from Year 1 activities are also shaded in **light yellow**.

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania		
IR 1.1: Stewardship	1.1.1: Market stewardship capacity to triangulate market level and private sector data improved	1	Number of public-private dialogue (PPD) platforms that regularly share and discuss data from public and private sectors in targeted health markets.	X		X			X			X							X			X	X		
		2	Number of policy modifications approved by market stewards that are informed by private sector health market data.	X						X			X							X					
		3	Number of events convened with the support of FHM Engage to bring together public, private sector actors, and donor actors to discuss the root causes of a health market challenge.	X		X	X			X	X	X		X	X		X	X			X	X	X	X	X
	1.1.2: Market stewards consider other market actors and information to create inclusive decision-making processes	4	Number of private sector actors engaged in collaboration with public sector actors to address an identified market challenge.	X		X	X			X	X	X	X	X		X	X			X	X	X	X	X	
		5	Number of policies developed with support from FHM Engage to strengthen the enabling environment for private sector participation in a given health market.	X						X	X			X	X		X		X					X	
		6	Number of private sector enterprises that engaged with the USG to support U.S. Foreign Assistance objectives [USG Indicator PSE-2].	X		X	X				X	X	X	X	X		X	X			X	X	X	X	X
1.1.3: Market actors increasingly engage in joint programs or partnerships through joint investments	6	Number of private sector enterprises that engaged with the USG to support U.S. Foreign Assistance objectives [USG Indicator PSE-2].	X		X	X			X	X	X	X	X		X	X			X	X	X	X	X		

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania
	7	Number of new programs or partnerships that include multiple market actor categories established through project support.	X												X	X			X		X		X
	8	Number of USG engagements jointly undertaken with the private sector to achieve a U.S. foreign assistance objective [USG Indicator PSE-1].	X		X	X		X	X	X		X	X		X	X			X	X	X		X
Financing																							
1.2.1: Private sector increases participation in health markets through improved incentives	9	Number of technical resources developed or adapted with project assistance to improve products or approaches for private-sector health financing.						X											X	X			X
	10	Number of private sector actors participating in government financing.						X															X
	11	Number of private sector actors trained in financial management and/or business skills with FHM Engage support.						X															X
	12	Number of private sector actors receiving non-financial resources to improve or expand service delivery.						X															X
	13	Number of private sector enterprises with increased access to finance due to USG assistance [USG Indicator EG.2-12].						X															X
1.2.2: Private sector actors have increased access to financing through public, private, and donor funding channels	14	Number of institutions that develop or improve financial products targeting private sector actors with FHM Engage support.						X															X
	15	Value of financing provided to the private sector providers with FHM-Engage support.						X															X

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania	
Rules and norms	16	Number of policy changes that have been adopted with FHM Engage support to enhance the enabling environment for the quality of private sector actors.	X						X						X	X	X					X	X	
	17	Number of policy changes that have been adopted with FHM Engage support to enhance the enabling environment for private sector actor market entry or expansion.	X						X								X			X				
	18	Number of policy changes that have been adopted with FHM Engage support that improve conditions for private health sector data regulation, data use, and/or data sharing agreements.								X	X		X	X					X					
	19	Number of FHM Engage technical contributions to health policy and/or strategy that specify the role of private sector actors.	X						X	X	X	X	X	X		X	X	X	X	X	X	X	X	X
	20	Number of private health providers, private facility networks or aggregation models strengthened through modifications to organizational structures, policies, or capacity with FHM Engage support.														X				X			X	
	21	Number of private sector actors joining aggregator/representative networks through FHM Engage support.																		X			X	
I.3.1: Health market regulations and rules facilitate private sector participation																								
I.3.2: Private sector actors and networks improved to engage with health markets																								

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania
Market Intelligence																							
1.4.1: Private sector actors increasingly collect and share product and service data with the public sector through harmonized data systems	22	Number of individuals supported by FHM Engage to improve data collection, reporting, analysis and/or use.								X	X	X	X					X		X			X
	23	Number of analytical tools created with FHM Engage support to facilitate analysis of health market information.	X							X	X	X	X					X		X			X
	24	Percentage of FHM Engage-supported market actors reported improved understanding of market information.	X							X	X	X	X					X		X			X
	25	Percentage of FHM Engage-supported market actors reporting improved use of market information.	X							X	X	X	X					X		X			X
	26	Number of public and private sector actor data sources integrated to address priority use cases.									X	X	X					X					X
	27	Number of health information data collection and/or reporting processes supported by FHM Engage that transition to independent implementation by the involved market stewards and data generators.									X		X										X
Quality																							
2.1.1: Appropriate QA/QI standards for services and products established for the private-sector health market	28	Number of private sector providers and/or networks who are introduced to or are receiving QA/QI protocols, clinical guidelines, or standards through FHM Engage support.													X	X							X

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania	
2.1.2: Client satisfaction with private sector quality improved.	29	Number of private sector actors receiving training or other types of capacity-building support regarding QA/QI protocols, clinical guidelines, or clinical standards through FHM Engage support.													X	X							X	
	30	Number of private sector actors receiving support on quality through FHM Engage who have reported a change in facility policies or procedures regarding QA/QI, clinical guidelines, or clinical standards.													X	X								X
	31	Percent of private sector actors receiving support on quality through FHM Engage who are adhering to QA/QI protocols, clinical guidelines, or clinical standards.													X	X								X
	32	Number of distributors importing quality-assured products for private sector providers and/or network distribution.							X									X						X
	33	Average FHM quality index score for a representative sample of private sector actors within FHM Engage geographies.													X							X		
Supply																								
2.2.1: Private sector product and service offerings better aligned to client demand.	34	Number of private sector health market analysis activities co-implemented with private sector actors through FHM Engage support.	X					X	X	X	X	X	X		X	X	X	X		X	X		X	
	35	Number of private sector actors reporting a change in service or product offering based on activities implemented with project support.						X							X	X	X					X		X

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania	
2.2.2: Private sector product and service offerings expanded or improved.	36	Number and percentage of health products in target area available through private sector actors with FHM Engage support.						X							X		X					X	X	
	37	Number and percentage of priority health services delivered by private sector actors with FHM Engage support.						X							X		X					X	X	
	38	Number of new partnerships between private sector actors and other market actors that targets shifting the supply of a product or service created through FHM Engage support.	X						X							X	X	X		X		X		X
	39	Number of private sector actors who are registered through FHM Engage support.																X		X				X
	40	Number of private sector actors receiving FHM Engage support working on accreditation with local regulatory authorities or private sector accreditation providers.	X							X														
Demand																								
2.3.1 Private sector service and product utilization increased across targeted market segments.	41	Number of individuals from targeted market segments reached with demand generation and SBC campaign strategies and messages supported by FHM Engage.														X							X	
	42	Number of individuals from targeted market segments utilizing product/services from demand generation/SBC campaigns from areas supported by FHM Engage.														X							X	

Global Sub-IR	Ind.	Global Indicator Name	I.1.A	I.1.B	I.1.C	I.1.D	I.2A	I.2.B	I.3.A	I.4.A	I.4.B	I.4.C	I.4.D	I.4E	2.1.A	2.1.B	2.2.A	2.2.B	2.2.C	2.3.A	2.3.B	Liberia	Tanzania
	43	Percentage of private sector entities demonstrating improved health communication/advertising as a result of USG assistance.													X							X	X
	44	Number of private sector actors leading FHM Engage supported demand generation activities related to P/SBCC.													X							X	
Health outcome-related indicators																							
	45	Number of CYPs, disaggregated by method type, generated in target area with support from FHM-Engage.						X							X		X		X			X	X
	46	Number of pregnant women receiving at least 4 ANC checks in FHM-Engage supported private sector facilities.																					
	47	Number of cases of child diarrhea treated in USG-assisted programs [HL 6.6].														X							X
	48	Number of cases of childhood pneumonia treated in USG-assisted programs [HL 6.6].														X							X
	49	Number/percent of women who were treated for malaria during their most recent pregnancy by FHM-Engage supported private providers.																					
	50	Number of malaria rapid diagnostic tests (RDTs) distributed with USG funds (Output) [HL 3.1-2].																					
	51	Number of institutional deliveries carried out in FHM-Engage supported private sector facilities.																					

Achievements in Year 1

Table 2 below summarizes the data for each of the performance indicators. The reporting for Year 1 is only reflective of the indicators for IRI (indicators 1-27), though this table includes all 51 indicators for reference. While the reporting for Year 1 reflects all of the IRI indicators, the table shows non-zero values for only 7 indicators (indicators 1, 3, 4, 6, 11, 19, and 20). This is to be expected for a few reasons.

The first reason is the timing of Year 1 activities. The Year 1 work plan was approved in April 2022, resulting in a shorter timeframe for producing results. Second – and connected to timing – most of the performance indicators measure FHM Engage’s anticipated outcomes. Outcomes, because they reflect behavior change, typically take longer to manifest themselves in ways that are measurable. With the truncated period of implementation in Year 1, we expect to see fewer behavior changes that can then be measured and reported on through our primarily outcome-focused indicator set. Third, Year 1 of FHM Engage was heavily focused on start-up of activities and building relationships with partners. This foundational work has set up FHM Engage for success in future years and progress is already well under way in Year 2. However, because the Year 1 activities were heavily focused on the foundational aspects of the work, the primary results are outputs, such as foundational briefs, reports, and literature reviews. Fewer of the performance indicators are meant to measure these types of outputs.

TABLE 2: SUMMARY OF RESULTS

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
IR 1.1: Stewardship								
1.1.1: Market stewardship capacity to triangulate market level and private sector data improved	1	Number of public-private dialogue (PPD) platforms that regularly share and discuss data from public and private sectors in targeted health markets.	1	Health area: HIV/AIDS (1)	Output	By health area	TBD	TBD
	2	Number of policy modifications approved by market stewards that are informed by private sector health market data.	0	N/A	Outcome	By private sector actor type, by gender (female owned business, or gender of private provider)	TBD	TBD
1.1.2: Market stewards consider other market actors and information to create inclusive decision-making processes	3	Number of events convened with the support of FHM Engage to bring together public, private sector actors, and donor actors to discuss the root causes of a health market challenge.	12	Country: Global (5) Liberia (3) Tanzania (4)	Output	By country	TBD	TBD
	4	Number of private sector actors engaged in collaboration with public sector actors to address an identified market challenge.	13	Private sector actor type: For-profit commercial entities (5) Private social enterprise (1) Business, trade, and industry associations (4) Other (3)	Output	By private sector actor type	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
1.1.3: Market actors increasingly engage in joint programs or partnerships through joint investments	5	Number of policies developed with support from FHM Engage to strengthen the enabling environment for private sector participation in a given health market.	0	N/A	Outcome	By type of policy, by supporting function	TBD	TBD
	6	Number of private sector enterprises that engaged with the USG to support U.S. Foreign Assistance objectives [USG Indicator PSE-2].	14	<i>Private sector actor type:</i> For-profit commercial entities (6) Private financial enterprises (2) Business, trade, and industry associations (6) <i>US foreign assistance objective:</i> Health (14) <i>Size of private sector enterprise:</i> Small (10-50 employees) (6) Large (100+ employees) (8) <i>Origin of private sector enterprise:</i> US-Based (1) Host country-based (8) Third country-based (5)	Output	By private sector actor type, by US Foreign assistance objective, size of private sector enterprise, origin of private sector enterprise	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
	7	Number of new programs or partnerships that include multiple market actor categories established through project support.	0	N/A	Outcome	By private sector actor type, by partnership objective, by gender (female owned business, or gender of private provider)	TBD	TBD
	8	Number of USG engagements jointly undertaken with the private sector to achieve a U.S. foreign assistance objective [USG Indicator PSE-1].	0	N/A	Output	By private sector actor type, by US Foreign assistance objective, size of private sector enterprise, origin of private sector enterprise, by gender (female owned business, or gender of private provider)	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
1.2.1: Private sector increases participation in health markets through improved incentives	9	Number of technical resources developed or adapted with project assistance to improve products or approaches for private-sector health financing.	0	N/A	Output	By supply side vs. demand side financing approaches, and then disaggregation on type of approach or product (i.e., loan product vs. purchasing, arrangements, type of technical resources, etc.)	TBD	TBD
	10	Number of private sector actors participating in government financing.	0	N/A	Output	By private sector actor type, by gender (gender of private provider or female-owned business), type of financing scheme.	TBD	TBD
	11	Number of private sector actors trained in financial management and/or business skills with FHM Engage support.	34	Sex: Female (29) Male (5) Private sector actor type: Other (34)	Output	By sex, by private sector actor type	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
1.2.2: Private sector actors have increased access to financing through public, private, and donor funding channels	12	Number of private sector actors receiving non-financial resources to improve or expand service delivery.	0	N/A	Output	By type of non-financial resource, By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD
	13	Number of private sector enterprises with increased access to finance due to USG assistance [USG Indicator EG.2-12].	0	N/A	Output	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD
	14	Number of institutions that develop or improve financial products targeting private sector actors with FHM Engage support.	0	N/A	Outcome	By type of institution, By private sector actor type, by gender (gender of private provider or female-owned business), type of support	TBD	TBD
	15	Value of financing provided to the private sector providers with FHM-Engage support.	0	N/A	Outcome	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
1.3.1: Health market regulations and rules facilitate private sector participation	16	Number of policy changes that have been adopted with FHM Engage support to enhance the enabling environment for the quality of private sector actors.	0	N/A	Outcome	By type of policy change	TBD	TBD
	17	Number of policy changes that have been adopted with FHM Engage support to enhance the enabling environment for private sector actor market entry or expansion.	0	N/A	Outcome	By type of policy change	TBD	TBD
	18	Number of policy changes that have been adopted with FHM Engage support that improve conditions for private health sector data regulation, data use, and/or data sharing agreements.	0	N/A	Outcome	By type of policy change	TBD	TBD
	19	Number of FHM Engage technical contributions to health policy and/or strategy that specify the role of private sector actors.	14	Technical area: Stewardship (4) Financing (1) Rules and norms (2) Market intelligence (4) Multiple (3)	Outcome	By technical area	TBD	TBD
	20	Number of private health providers, private facility networks or aggregation models strengthened through modifications to organizational structures, policies, or capacity with FHM Engage support.	1	Private sector actor type: Business, Trade and Industry Associations (1) Type of modification: Capacity (1)	Output	By type of private sector actor model, by type of modification (structural, policy, capacity)	TBD	TBD
1.3.2: Private sector actors and networks improved to engage with health markets								

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
	21	Number of private sector actors joining aggregator/representative networks through FHM Engage support.	0	N/A	Output	By private sector actor type, By private facility network type	TBD	TBD
Market Intelligence	22	Number of individuals supported by FHM Engage to improve data collection, reporting, analysis and/or use.	0	N/A	Output	By stakeholder type, by gender	TBD	TBD
	23	Number of analytical tools created with FHM Engage support to facilitate analysis of health market information.	0	N/A	Output	By tool type (dashboards, visualizations, other formats)	TBD	TBD
	24	Percentage of FHM Engage-supported market actors reported improved understanding of market information.	0	N/A	Outcome	By stakeholder type, by gender	TBD	TBD
	25	Percentage of FHM Engage-supported market actors reporting improved use of market information.	0	N/A	Outcome	By stakeholder type, by gender	TBD	TBD
	26	Number of public and private sector actor data sources integrated to address priority use cases.	0	N/A	Outcome	By use case type	TBD	TBD
	27	Number of health information data collection and/or reporting processes supported by FHM Engage that transition to independent implementation by the involved market stewards and data generators.	0	N/A	Outcome	By stakeholder type	TBD	TBD
	1.4.1: Private sector actors increasingly collect and share product and service data with the public sector through harmonized data systems							

Global Sub-IR	Ind.	Global Indicator Name	Value for Year I	Disaggregation values	Type	Disaggregation	Baseline	Target
Quality 2.1.1: Appropriate QA/QI standards for services and products established for the private-sector health market	28	Number of private sector providers and/or networks who are introduced to or are receiving QA/QI protocols, clinical guidelines, or standards through FHM Engage support.	0	N/A	Output	By type of private sector actor, by health area (FP, MNCH, HIV/AIDS, etc.), by gender (provider gender or female-owned business)	TBD	TBD
	29	Number of private sector actors receiving training or other types of capacity-building support regarding QA/QI protocols, clinical guidelines, or clinical standards through FHM Engage support.	0	N/A	Output	By type of private sector actor, by health area (FP, MNCH, HIV/AIDS, etc.), by gender (provider gender or female-owned business)	TBD	TBD
	30	Number of private sector actors receiving support on quality through FHM Engage who have reported a change in facility policies or procedures regarding QA/QI, clinical guidelines, or clinical standards.	0	N/A	Outcome	By type of private sector actor, by health area (FP, MNCH, HIV/AIDS, etc.), by gender (provider gender or female-owned business)	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year I	Disaggregation values	Type	Disaggregation	Baseline	Target
2.1.2: Client satisfaction with private sector quality improved.	31	Percent of private sector actors receiving support on quality through FHM Engage who are adhering to QA/QI protocols, clinical guidelines, or clinical standards.	0	N/A	Outcome	By type of private sector actor, by health area (FP, MNCH, HIV/AIDS, etc.), by gender (provider gender or female-owned business)	TBD	TBD
	32	Number of distributors importing quality-assured products for private sector providers and/or network distribution.	0	N/A	Type of Indicator: Outcome	By type of private sector actor, by health area (FP, MNCH, HIV/AIDS, etc.), by gender (provider gender or female-owned business)	TBD	TBD
	33	Average FHM quality index score for a representative sample of private sector actors within FHM Engage geographies.	0	N/A	Outcome	Type of private sector providers/networks	TBD	TBD
Supply								
2.2.1: Private sector product and service offerings better aligned to client demand.	34	Number of private sector health market analysis activities co-implemented with private sector actors through FHM Engage support.	0	N/A	Output	By type of private sector actor, By country and type of health market.	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year I	Disaggregation values	Type	Disaggregation	Baseline	Target
2.2.2: Private sector product and service offerings expanded or improved.	35	Number of private sector actors reporting a change in service or product offering based on activities implemented with project support.	0	N/A	Outcome	By type of private sector actor, by change in service, product, or other client offering	TBD	TBD
	36	Number and percentage of health products in target area available through private sector actors with FHM Engage support.	0	N/A	Output	By health area (FP, MNCH, HIV/AIDS, etc.), by type of private sector actor	TBD	TBD
	37	Number and percentage of priority health services delivered by private sector actors with FHM Engage support.	0	N/A	Output	By health area (FP, MNCH, HIV/AIDS, etc.), by type of private sector actor	TBD	TBD
	38	Number of new partnerships between private sector actors and other market actors that targets shifting the supply of a product or service created through FHM Engage support.	0	N/A	Output	By type of partners involved, type of partnership created (i.e., equipment focused, commodity sharing, etc.)	TBD	TBD
	39	Number of private sector actors who are registered through FHM Engage support.	0	N/A	Output	By type of private sector actor	TBD	TBD
	40	Number of private sector actors receiving FHM Engage support working on accreditation with local regulatory authorities or private sector accreditation providers.	0	N/A	Outcome	By type of private sector actor	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year I	Disaggregation values	Type	Disaggregation	Baseline	Target
Demand 2.3.1 Private sector service and product utilization increased across targeted market segments.	41	Number of individuals from targeted market segments reached with demand generation and SBC campaign strategies and messages supported by FHM Engage.	0	N/A	Output	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD
	42	Number of individuals from targeted market segments utilizing product/services from demand generation/SBC campaigns from areas supported by FHM Engage.	0	N/A	Outcome	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD
	43	Percentage of private sector entities demonstrating improved health communication/advertising as a result of USG assistance.	0	N/A	Outcome	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD
	44	Number of private sector actors leading FHM Engage supported demand generation activities related to P/SBCC.	0	N/A	Outcome	By private sector actor type, by gender (gender of private provider or female-owned business)	TBD	TBD

Global Sub-IR	Ind.	Global Indicator Name	Value for Year 1	Disaggregation values	Type	Disaggregation	Baseline	Target
Health outcome-related indicators	45	Number of CYPs, disaggregated by method type, generated in target area with support from FHM-Engage.	0	N/A	Output	By method type and market segment.	TBD	TBD
	46	Number of pregnant women receiving at least 4 ANC checks in FHM-Engage supported private sector facilities.	0	N/A	Outcome	By private sector actor type, by country	TBD	TBD
	47	Number of cases of child diarrhea treated in USG-assisted programs [HL 6.6].	0	N/A	Output	By private sector actor type, by country	TBD	TBD
	48	Number of cases of childhood pneumonia treated in USG-assisted programs [HL 6.6].	0	N/A	Output	By private sector actor type, by country	TBD	TBD
	49	Number/percent of women who were treated for malaria during their most recent pregnancy by FHM-Engage supported private providers.	0	N/A	Outcome	By private sector actor type, by country	TBD	TBD
	50	Number of malaria rapid diagnostic tests (RDTs) distributed with USG funds (Output) [HL 3.1-2].	0	N/A	Output	By private sector actor type, by country	TBD	TBD
	51	Number of institutional deliveries carried out in FHM-Engage supported private sector facilities.	0	N/A	Outcome	By private sector actor type, by country	TBD	TBD

About FHM Engage

Frontier Health Markets (FHM) Engage is a five-year cooperative agreement (7200AA21CA00027) funded by the United States Agency for International Development. We work to improve the market environment for greater private sector participation in the delivery of health products and services and to improve equal access to and uptake of high-quality consumer driven health products, services, and information. Chemonics International implements FHM Engage in collaboration with Core Partners: Results for Development (co-technical lead), Pathfinder, and Zenysis. FHM Engage Network Implementation Partners include ACCESS Health India, Africa Christian Health Association Platform, Africa Healthcare Federation, Amref Health Africa, Ariadne Labs, CERRHUD, Insight Health Advisors, Makerere University School of Public Health, Metrics for Management, Solina Group, Strategic Purchasing Africa Resource Center, Scope Impact, Stage Six, Strathmore University, Total Family Health Organization, and Ubora Institute.

© **Chemonics 2022**. All rights reserved.

1275 New Jersey Ave. SE, Ste 200,
Washington, DC 20003